FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to pharmacy. There is disclosed new preparation. Controlled-release Proxodolol is prepared effectively and conveniently with applying one or more mixed swelling or gelling components, an active component and pharmaceutically acceptable filler. It is preferential to apply a tableted preparation containing Proxodolol dosed 120 mg, hypromellose and pharmaceutically acceptable fillers, e.g. microcrystalline cellulose, calcium stearate and aerosil. New pharmaceutical forms with a suitable Proxodolol release profile allow reducing number of daily dosages while concentration of active component is constant within a therapeutic dose.
EFFECT: stable kinetic indicators of active material delivery.
8 cl, 5 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIDEPRESSANT PHARMACEUTICAL COMPOSITION OF PROLONGED ACTION | 2008 |
|
RU2377991C1 |
| PHARMACEUTICAL COMPOSITION OF PROLONGED ACTION FOR CORRECTION OF PSYCHOSOMATIC MANIFESTATIONS | 2009 |
|
RU2424807C2 |
| PROLONGED ACTION PHARMACEUTICAL COMPOSITION BASED ON 5-ETHOXY-2-[2-(MORPHOLINO)-ETHYLTHIO]BENZIMIDAZOLE DIHYDROCHLORIDE AND/OR BASE (APHOBAZOLUM) | 2017 |
|
RU2694837C2 |
| TACROLIMUS FOR IMPROVED TREATMENT OF PATIENTS WITH GRAFTS | 2009 |
|
RU2574006C2 |
| ANTI-TUBERCULOSIS MEDICATION BASED ON 4-THIOUREIDOIMINOMETHYLPYRIDINIUM PERCHLORATE, METHOD OF ITS OBTAINING AND METHOD OF TREATMENT | 2010 |
|
RU2423977C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ALIMAMAZINE TARTRATE | 2017 |
|
RU2659200C1 |
| METHOD OF PRODUCING AN ANTIOXIDANT AGENT IN THE FORM OF A TABLET WITH PROLONGED EFFECT | 2019 |
|
RU2712445C1 |
| COMPOSITION FOR TREATING DISTURBED INNERVATION (VERSIONS) | 2013 |
|
RU2536269C1 |
| SYSTEM FOR DELIVERY OF 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE FOR ORAL ADMINISTRATION IN FORM OF GASTRORETENTIVE TABLET | 2019 |
|
RU2734970C1 |
| TABLETTED PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING IT | 2013 |
|
RU2539375C1 |
